With box warnings

Without box warnings

Branded

Generic

2 results

mekinist
(trametinib)
Novartis Pharmaceuticals Corporation
Usage: MEKINIST is indicated for treating unresectable or metastatic melanoma, metastatic non-small cell lung cancer (NSCLC), locally advanced or metastatic anaplastic thyroid cancer, unresectable or metastatic solid tumors, and low-grade glioma with BRAF V600E/K mutations, in combination with dabrafenib, as per FDA-approved tests.
tafinlar
(dabrafenib)
Novartis Pharmaceuticals Corporation
Usage: TAFINLAR is indicated for the treatment of BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma, non-small cell lung cancer, anaplastic thyroid cancer, solid tumors, and low-grade glioma in patients aged one year and older. It should not be used in colorectal cancer or wild-type BRAF tumors.

Medications for Low Grade Glioma

mekinist